ALLARITY THERAPEUTICS INC (ALLR) Stock Price, Quote, News and Overview
NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD
ALLR Quote, Performance and Key Statistics
ALLARITY THERAPEUTICS INC
NASDAQ:ALLR (1/23/2025, 8:42:41 PM)
After market: 1.2899 -0.03 (-2.28%)1.32
+0.31 (+30.69%)
The current stock price of ALLR is 1.32 USD. In the past month the price increased by 33.32%. In the past year, price decreased by -99.49%.
ALLR Latest News, Press Releases and Analysis
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to...
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
ALLR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.88 | 301.60B | ||
| AMGN | AMGEN INC | 14.46 | 149.37B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862.22 | 113.24B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.29 | 76.33B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.8 | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.18B |
Related screens
About ALLR
Company Profile
Allarity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2021-12-21. Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The firm is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. The company has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
Company Info
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Company Website: https://allarity.com/
Investor Relations: https://allarity.com/investors/
Phone: 14014264664
ALLR FAQ
What is the price of ALLR?
The current price of ALLR is 1.32 USD.
What is the symbol for ALLARITY THERAPEUTICS INC?
The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.
On which exchange is ALLR listed?
ALLR is listed on the Nasdaq exchange.
Is ALLR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ALLR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ALLR.
Does ALLR pay dividends?
ALLR does not pay a dividend.
What is the Price/Earnings (PE) ratio of ALLR?
ALLR does not have a PE ratio as the earnings reported over the last twelve months were negative (-933.21).
What is the Short Interest ratio of ALLR?
The outstanding short interest for ALLR is 6.33% of its float.
ALLR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALLR. When comparing the yearly performance of all stocks, ALLR is a bad performer in the overall market: 97.03% of all stocks are doing better.
ALLR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. The financial health of ALLR is average, but there are quite some concerns on its profitability.
ALLR Financial Highlights
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -933.21. The EPS increased by 99.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -95.31% | ||
| ROE | -149.82% | ||
| Debt/Equity | 0 |
ALLR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ALLR. The Buy consensus is the average rating of analysts ratings from 6 analysts.